PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort. This is an ASCO Meeting Abstract from the 2024 ASCO ...
Progressing lesions of 25 patients with GISTs refractory to ripretinib were sequenced for KIT resistance mutations. Resistant genotypes were validated and characterized using novel cell line models ...
In nine patients with chronic lymphocytic leukemia that responded to the noncovalent BTK inhibitor pirtobrutinib and then developed resistance, analysis revealed a number of new mutations in the BTK ...
In a new study published in Science Signaling titled, “Restoration of striatal neuroprotective pathways by kinase inhibitor treatment of Parkinson’s linked-LRRK2 mutant mice,” researchers from ...
- Preclinical research and clinical safety and tolerability data supports continued development of IkT-148009 to potentially slow or halt progression of Parkinson's disease BOSTON and ATLANTA, Nov. 29 ...
Early-phase clinical trials involving PIM-1 kinase inhibitors look promising. In the evolving landscape of myelofibrosis (MF) ...
Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results